About: SARS-CoV-2 Antibody Responses Correlate with Resolution of RNAemia But Are Short-Lived in Patients with Mild Illness

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: SARS-CoV-2 Antibody Responses Correlate with Resolution of RNAemia But Are Short-Lived in Patients with Mild Illness Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	SARS-CoV-2 Antibody Responses Correlate with Resolution of RNAemia But Are Short-Lived in Patients with Mild Illness
Creator	Hogan, Catherine Rogers, Angela Biohub, Chan Francisco, San Jardetzky, Theodore Kim, Peter Pinsky, Benjamin Pham, Tho Sahoo, Malaya Shah, Nigam Blish, Catherine Boyd, Scott Gombar, Saurabh Najeeb, Javaria Otrelo-Cardoso, Ana Powell, Abigail Rustagi, Arjun Röltgen, Katharina Stevens, Bryan Wang, Taia Zehnder, James Cochran, Jennifer Huang, Chunhong Hunter, Molly Manalac, Justin Nadeau, Kari Tibshirani, Robert Wirz, Oliver Yamamoto, Fumiko
Source	MedRxiv; Medline; PMC
abstract	SARS-CoV-2-specific antibodies, particularly those preventing viral spike receptor binding domain (RBD) interaction with host angiotensin-converting enzyme 2 (ACE2) receptor, could offer protective immunity, and may affect clinical outcomes of COVID-19 patients. We analyzed 625 serial plasma samples from 40 hospitalized COVID-19 patients and 170 SARS-CoV-2-infected outpatients and asymptomatic individuals. Severely ill patients developed significantly higher SARS-CoV-2-specific antibody responses than outpatients and asymptomatic individuals. The development of plasma antibodies was correlated with decreases in viral RNAemia, consistent with potential humoral immune clearance of virus. Using a novel competition ELISA, we detected antibodies blocking RBD-ACE2 interactions in 68% of inpatients and 40% of outpatients tested. Cross-reactive antibodies recognizing SARS-CoV RBD were found almost exclusively in hospitalized patients. Outpatient and asymptomatic individuals’ serological responses to SARS-CoV-2 decreased within 2 months, suggesting that humoral protection may be short-lived.
has issue date	2020-08-17(xsd:dateTime)
bibo:doi	10.1101/2020.08.15.20175794
bibo:pmid	32839786
has license	cc-by-nc-nd
sha1sum (hex)	3cea44076951957b8a3072c1a8a7337525c24973
schema:url	https://doi.org/10.1101/2020.08.15.20175794
resource representing a document's title	SARS-CoV-2 Antibody Responses Correlate with Resolution of RNAemia But Are Short-Lived in Patients with Mild Illness
has PubMed Central identifier	PMC7444305
has PubMed identifier	32839786
schema:publication	medRxiv
resource representing a document's body	covid:3cea44076951957b8a3072c1a8a7337525c24973#body_text
is schema:about of	named entity 'COVID-19' named entity 'patients' named entity 'Resolution' named entity 'Title' named entity 'Mild' named entity 'patients' named entity 'asymptomatic' named entity 'affect' named entity 'binding domain' named entity 'specific' named entity 'But' named entity 'Responses' named entity 'plasma' named entity 'angiotensin-converting enzyme 2' named entity 'clinical outcomes' named entity 'ACE2' named entity 'receptor binding domain' named entity 'interaction' named entity 'RBD' named entity 'RT-PCR' named entity 'antigen' named entity '8.5' named entity 'high levels' named entity 'COVID' named entity 'plasma' named entity 'rRT-PCR' named entity 'SARS-CoV-2' named entity 'IgG' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'preprint' named entity 't-tests' named entity 'COVID' named entity 'RBD' named entity 'ACE2' named entity 'medRxiv' named entity 'symptom' named entity 'serological' named entity 'serology test' named entity 'IQR' named entity 'nasopharyngeal swab' named entity 'infection' named entity 'serological' named entity 'preprint' named entity 'coronavirus disease' named entity 'serology' named entity 'antibody' named entity 'immunogenic' named entity 'protein' named entity 'antibodies' named entity 'RBD' named entity 'preprint' named entity 'ICU'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software